Nymox Pharmaceutical Corporati (NYMX)

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs and diagnostic devices. Its products under development include NX-1207, a treatment for benign prostatic hyperplasia. The companys marketed products include AlzheimAlert, a urinary test that aids physicians in the diagnosis of Alzheimer's disease; and NicAlert and TobacAlert tests that use urine or saliva to detect use of and exposure to tobacco products. Nymox Pharmaceutical was founded in 1989 and is headquartered in Saint-Laurent, Canada with an additional office in St.-Laurent, Canada.

For the six months ended 30 June 2006, Nymox Pharmaceutical Corporation's revenues decreased 1% to $216K. Net loss increased 33% to $2.4M. Revenues reflect a decrease in sales from United States market. Net loss also reflects an increase in research & development expenses, increased stock based compensation expense, higher cost of sales, higher interest charges and increased depreciation & amortization expense.